Wells Fargo & Company Unity Biotechnology, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.4 - $4.27 $24 - $264	-62 Reduced 5.67%	1,032 $0
Q2 2022 Aug 12, 2022	SELL	$0.56 - $1.29 $71 - $163	-127 Reduced 10.4%	1,094 $0
Q1 2022 May 16, 2022	BUY	$0.72 - $1.86 $144 - $373	201 Added 19.71%	1,221 $2,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $273 - $665	210 Added 25.93%	1,020 $1,000
Q2 2021 Aug 16, 2021	SELL	$4.15 - $6.3 $37,740 - $57,292	-9,094 Reduced 91.82%	810 $4,000
Q1 2021 May 13, 2021	SELL	$5.51 - $9.42 $305,887 - $522,951	-55,515 Reduced 84.86%	9,904 $60,000
Q4 2020 Feb 09, 2021	BUY	$3.42 - $6.36 $153,021 - $284,565	44,743 Added 216.4%	65,419 $343,000
Q3 2020 Nov 05, 2020	SELL	$2.94 - $12.43 $352,561 - $1.49 Million	-119,919 Reduced 85.29%	20,676 $71,000
Q2 2020 Aug 13, 2020	BUY	$5.28 - $9.67 $629,603 - $1.15 Million	119,243 Added 558.46%	140,595 $1.22 Million
Q1 2020 May 14, 2020	BUY	$5.0 - $7.6 $106,760 - $162,275	21,352 New	21,352 $124,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $16.1M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.